{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T13:56:43.806852",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 138,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "survival",
        "long-term survival",
        "recurrence-free survival",
        "perioperative mortality",
        "treatment-related mortality",
        "deaths"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; mRECIST)",
        "overall response rate (ORR)",
        "tumor response rate",
        "tumour response (RECIST criteria)",
        "tumour response (mRECIST)",
        "response (CR, PR, mRECIST)",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (RECIS systems)",
        "partial response (PR)",
        "partial response (radiological, independently assessed)",
        "partial response",
        "minor response (radiological, independently assessed; reduction of tumour size by 25 to 50%)",
        "complete response (CR)",
        "complete remission",
        "objective tumour response",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "stable disease (SD)",
        "stable disease (radiological, independently assessed; for at least 16 weeks)",
        "clinical benefit rate (CBR)",
        "tumor reduction",
        "tumour viability (mRECIST)",
        "number needed to treat (NNT)"
      ],
      "progression_measures": [
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (PFS; mRECIST)",
        "progression-free survival (modified RECIST criteria)",
        "progression-free survivorship",
        "time to progression (TTP)",
        "time to progression",
        "time to progression of the tumor",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to radiological disease progression",
        "time to deterioration",
        "time to clinically meaningful worsening (EORTC QLQ-C30)",
        "time to clinically meaningful worsening (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EQ-5D)",
        "time to quality of life impairment (EORTC QLQ-C30)",
        "time to quality of life impairment (EORTC QLQ-HCC18)",
        "tumour progression",
        "disease progression",
        "disease recurrence",
        "recurrence",
        "recurrence risk",
        "tumour relapse",
        "local control",
        "local tumour control",
        "bridging therapy (prevention of progression)",
        "early detection of local recurrence",
        "early detection of de novo tumor"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse reactions (general)",
        "adverse events (Grade ≥ 3)",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "grade 3-4 adverse events",
        "grade 5 adverse events",
        "treatment-emergent adverse events (TEAEs)",
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "drug withdrawal due to adverse events",
        "discontinuation of treatment due to adverse events",
        "dropout rate for toxicity",
        "toxicity",
        "tolerability",
        "side-effects (biopsy)",
        "complications (general)",
        "post-treatment complications",
        "complication incidence",
        "serious adverse events",
        "serious complications",
        "long-term treatment-related complications",
        "infections",
        "bleeding",
        "haemorrhage",
        "brain/gastrointestinal bleeding",
        "brain haemorrhage",
        "tumour haemorrhage",
        "haemorrhagic events",
        "arterial hypertension",
        "hypertension",
        "hypertension (grade 3/4)",
        "proteinuria",
        "renal events",
        "renal failure",
        "hepatic impairment",
        "hepatic insufficiency",
        "liver failure",
        "liver disorders",
        "hepatic encephalopathy",
        "ascites",
        "jaundice",
        "increased serum bilirubin",
        "increased alanine aminotransferase (ALT)",
        "increased aspartate aminotransferase (AST)",
        "transient increase in transaminases",
        "gastrointestinal disorders",
        "gastrointestinal perforation",
        "intestinal failure",
        "nausea",
        "vomiting",
        "diarrhoea",
        "constipation",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "dry skin",
        "rash",
        "skin rash",
        "skin rash or desquamation",
        "dermatological toxicities",
        "desquamation",
        "palmar rash",
        "hand-foot syndrome",
        "hand-foot skin reaction",
        "hand feeding reactions (grade 3/4)",
        "erythema",
        "pruritus",
        "alopecia",
        "acne",
        "dermatitis exfoliative",
        "skin desquamation",
        "hyperkeratosis",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "myalgia",
        "muscle spasms",
        "arthralgia",
        "back pain",
        "limb pain",
        "pain",
        "abdominal pain",
        "abdominal swelling",
        "fatigue",
        "asthenia",
        "weight loss",
        "decreased weight",
        "loss of appetite",
        "decreased appetite",
        "anorexia",
        "dysphonia",
        "cough",
        "dyspnoea",
        "shortness of breath",
        "pleural effusion",
        "respiratory failure",
        "cardiac ischaemia",
        "myocardial ischaemia",
        "myocardial infarction",
        "cardiac infarction",
        "congestive heart failure",
        "cerebral vascular accident",
        "sudden death",
        "epilepsy",
        "sepsis",
        "infections",
        "influenza like illness",
        "infusion reactions",
        "immuno-mediated hepatitis",
        "hypothyroidism",
        "hyperthyroidism",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypoglycaemia",
        "hypophosphataemia",
        "lymphopenia",
        "leukopenia",
        "neutropenia",
        "anaemia",
        "thrombocytopenia",
        "lymphoedema (grade 3/4)",
        "arterial thromboembolic events",
        "thrombocytopenia",
        "folliculitis",
        "mucosal inflammation",
        "nutrition (as a symptom domain)",
        "body image (as a symptom domain)",
        "neurotoxicity",
        "peripheral sensory neuropathy",
        "depression",
        "psychological complaints",
        "psychosocial complaints",
        "distress",
        "concentration difficulties",
        "emotional impact",
        "physical complaints",
        "physical needs",
        "psychological needs",
        "social needs",
        "existential needs",
        "dysgeusia",
        "tinnitus",
        "flushing",
        "rhinorrhoea",
        "erectile dysfunction",
        "secondary cancer",
        "tumour seeding",
        "wound healing complications",
        "postoperative softening",
        "gallbladder abscess",
        "intraoperative complications",
        "serious complications",
        "morbidity",
        "mortality"
      ],
      "serious_events": [
        "serious adverse events",
        "serious complications",
        "grade 3-4 adverse events",
        "grade 5 adverse events",
        "treatment-related deaths",
        "treatment-related mortality",
        "sudden death"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "drug withdrawal due to adverse events",
        "discontinuation of treatment due to adverse events",
        "dropout rate for toxicity"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ-5D visual analogue scale (VAS)",
        "EQ VAS (Euro QoL visual analogue scale)",
        "EQ-5D health utility index (HUI)",
        "European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS)",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-Hep (Functional Assessment of Cancer Therapy - Hepatobiliary)",
        "EORTC QLQ-C30 function scales",
        "EORTC QLQ-HCC18 function scales",
        "EORTC QLQ-C30 symptom scales",
        "EORTC QLQ-HCC18 symptom scales",
        "SF-36",
        "visual analogue scale",
        "FHSI-8 questionnaire",
        "overall quality of life (measured with a validated and reliable instrument)",
        "quality of life weights (EQ-5D-3L-converted weights with Dolan tariff)",
        "state-specific quality-of-life weights"
      ],
      "functional_status": [
        "Eastern Cooperative Oncology Group Performance Status (ECOG PS)",
        "Child-Pugh scale (CTP)",
        "role functioning (as a symptom domain)"
      ],
      "symptom_measures": [
        "pain",
        "pain (EORTC QLQ-HCC18)",
        "fever",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "jaundice",
        "jaundice (EORTC QLQ-HCC18)",
        "cognitive functioning (EORTC QLQ-C30)",
        "symptoms (EORTC QLQ-C30 symptom scales, time to deterioration defined as a score increase by at least 10 points over baseline)",
        "symptoms (EORTC QLQ-HCC18 symptom scales, time to deterioration defined as a score increase by at least 10 points over baseline)",
        "deterioration in patient quality of life (EORTC QLQ-C30)",
        "deterioration in patient quality of life (EORTC QLQ-HCC18)",
        "time to quality of life impairment (EORTC QLQ-C30)",
        "time to quality of life impairment (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EORTC QLQ-C30)",
        "time to clinically meaningful worsening (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EQ-5D)",
        "nutritional status"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness",
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost per quality-adjusted life year (QALY)",
        "cost-benefit analysis",
        "cost-effectiveness analysis"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights (EQ-5D-3L-converted weights with Dolan tariff)",
        "state-specific quality-of-life weights"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "resource use estimates",
        "number needed to harm (NNH)"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)",
        "duration of treatment",
        "time to response",
        "tumour reduction",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "completeness of ablation (magnetic resonance imaging with contrast)",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (multiphase computed tomography)",
        "effectiveness of ablation (ultrasonography not appropriate)",
        "diagnosis (multiphasic CT and MRI, LI-RADS v2018)",
        "diagnosis (contrast-enhanced ultrasound)",
        "diagnosis (biopsy)",
        "diagnosis (immunohistochemistry markers)",
        "diagnosis (molecular genetic tests)",
        "histological and prognostic parameters (microscopic detection)",
        "immunohistochemical confirmation of hepatocytic origin",
        "genetic diagnosis (identification of subtypes)",
        "undesirable effects (general)",
        "adverse effects on development of hepatocellular carcinoma",
        "tumour seeding",
        "bridging therapy (prevention of progression)",
        "tumour viability (mRECIST)",
        "prognosis (BCLC staging system)",
        "Barcelona Clinic Liver Cancer (BCLC) Staging System",
        "AFIP grading",
        "WHO 3-member grading"
      ],
      "biomarkers": [
        "blood and tumour biomarkers correlated with clinical outcomes",
        "alpha-fetoprotein (AFP) monitoring"
      ],
      "pharmacokinetics": [
        "plasma pharmacokinetics parameters",
        "pharmacokinetic parameters"
      ],
      "laboratory_and_clinical_tests": [
        "vital signs",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography"
      ]
    }
  }
}